Skip to main content
main-content
Top

10-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: AMG 510 for KRAS mutation-positive NSCLC

Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the phase I trial of the novel KRAS inhibitor AMG 510, and comments on the next steps for the research (5:34).

Read more about AMG 510 here

Back to the WCLC 2019 conference hub

Related topics

Related content

Image Credits